Evidence map›Paper›PMID 32918587›Full record

ArticleCancer immunology, immunotherapy : CII2021

Reviving up dendritic cells can run cancer immune wheel in non-small cell lung cancer: a prospective two-arm study.

Asmaa M Zahran, Helal F Hetta, Shimaa Mansour, Ereny S Saad, Amal Rayan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Asmaa M ZahranClinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, 71515, Egypt.
Helal F HettaDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt. hettahf@ucmail.uc.edu.ORCID http://orcid.org/0000-0001-8541-7304
Shimaa MansourClinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, 71515, Egypt.
Ereny S SaadClinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.
Amal RayanClinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.
Assiut University · EGUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimLung cancer is the number one cause of cancer-related deaths. Dendritic cells (DCs) are heterogeneous components of innate immunity that play a crucial role in the anti-tumor T cell immunity and may represent a promising approach for tumor immunotherapy. In this study, we aimed to evaluate the frequency of the two major subsets of DCs; plasmacytoid dendritic cells (pDCs) and monocytic dendritic cells (mDCs) in non-small cell lung cancer (NCSLC) and correlating them with different clinicopathologic features and survival outcomes. PATIENTS AND

methodsThis study was a case-controlled one, included 50 patients with denovo pathologically confirmed NSCLC and 20 healthy controls of comparable age and gender. After diagnosis and staging of patients, the frequency of DCs was evaluated using flow cytometry.

resultsWe unveiled significantly reduced levels of pDCs (P = 0.024), and mDCs (P = 0.013) in NSCLC patients compared to controls. Furthermore, there was a significant accumulation of pDCs in non-metastatic patients compared to metastatic ones (P < 0.0001), while there was no significant (P = 0.6) differences in mDCs, and mDCs/pDCs ratio (P = 0.9). There was a Significant negative correlation (r = - 0.3, P = 0.04) between OS and mDCs. On the other hand, there was a significantly higher OS with pDCs ≥ 0.82 compared to patients with pDCs < 0.82, log rank Ch

conclusionDespite the controversy about the prognostic role of pDCs not only in NSCLC but also in other solid tumors, our study sheds light on the possible prognostic impact of pDCs and mDCs on treatment outcomes of NSCLC patients.

Indexed as

Disease SusceptibilityAdultAgedBiomarkersCarcinoma, Non-Small-Cell LungCase-Control StudiesDendritic CellsFemaleFlow CytometryHumansImmunophenotypingLung NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingBiomarkersDendritic cellsNon-small lung cancerOverall survival

Identifiers

PMID32918587
PMCPMC10992848
OpenAlexW3086848881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.